Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18999710 | ANTI-FUNGAL VHH ANTIBODIES | December 2024 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18667995 | CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA | May 2024 | March 2025 | Allow | 10 | 0 | 0 | No | No |
| 18508938 | CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18508501 | PD1 BINDING AGENTS | November 2023 | February 2025 | Abandon | 15 | 1 | 0 | Yes | No |
| 18497745 | METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY | October 2023 | May 2025 | Allow | 18 | 1 | 0 | No | No |
| 18485680 | CD3-DELTA/EPSILON HETERODIMER SPECIFIC ANTIBODIES | October 2023 | April 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18480825 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME | October 2023 | December 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18340600 | T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18333753 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | June 2023 | November 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 18333096 | HLA-DR CAR-T COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | June 2023 | May 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18190954 | T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF | March 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18188318 | T CELL-ANTIGEN COUPLER WITH Y182T MUTATION AND METHODS OF USES THEREOF | March 2023 | December 2023 | Allow | 9 | 1 | 0 | No | No |
| 18111179 | ANTI-PAD2 ANTIBODY FOR TREATING AND EVALUATING AUTOIMMUNE AND INFLAMMATORY DISEASES | February 2023 | March 2025 | Allow | 25 | 2 | 1 | No | No |
| 18020303 | ENRICHMENT OF T CELLS USING AN ANTI-C� ANTIBODY | February 2023 | August 2024 | Allow | 18 | 0 | 1 | No | No |
| 18005827 | ANTI-HUMAN MSLN ANTIBODY AND MSLN-TARGETING IMMUNE EFFECTOR CELL | January 2023 | December 2023 | Allow | 11 | 2 | 0 | No | No |
| 18153522 | ANTI-FC EPSILON-R1 ALPHA (FCER1A) ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND FCER1A AND CD3, AND USES THEREOF | January 2023 | June 2025 | Allow | 30 | 1 | 1 | No | No |
| 18062084 | MESOTHELIN-TARGETTING ANTIBODIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF | December 2022 | October 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17929573 | METHODS FOR DELAYING ONSET OF TYPE 1 DIABETES | September 2022 | May 2025 | Abandon | 33 | 5 | 1 | No | No |
| 17823223 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | August 2022 | August 2024 | Allow | 24 | 3 | 1 | No | No |
| 17820805 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | August 2022 | January 2025 | Allow | 29 | 2 | 2 | No | No |
| 17854904 | ANTIBODIES THAT BIND TO OX40 AND THEIR USES | June 2022 | December 2024 | Allow | 30 | 1 | 0 | No | No |
| 17807109 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | June 2022 | July 2023 | Allow | 13 | 1 | 1 | No | No |
| 17784988 | ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS | June 2022 | July 2025 | Allow | 37 | 0 | 0 | No | No |
| 17829778 | HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS | June 2022 | November 2022 | Allow | 5 | 1 | 1 | No | No |
| 17663148 | LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR | May 2022 | May 2024 | Allow | 24 | 3 | 1 | Yes | No |
| 17718372 | AGENTS WHICH INHIBIT GADS DIMERIZATION AND METHODS OF USE THEREOF | April 2022 | July 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17716737 | CANCER IMMUNOTHERAPY | April 2022 | January 2024 | Abandon | 22 | 3 | 0 | Yes | No |
| 17589088 | LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR | January 2022 | August 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17589093 | LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR | January 2022 | August 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17588703 | NYESO TCR | January 2022 | May 2024 | Allow | 28 | 1 | 0 | No | No |
| 17554180 | CD8 BINDING AGENTS | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17645004 | GENETICALLY MODIFIED NATURAL KILLER CELLS | December 2021 | June 2025 | Abandon | 42 | 2 | 1 | No | No |
| 17616113 | CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | December 2021 | August 2023 | Allow | 21 | 2 | 1 | No | No |
| 17496750 | Reagents and methods for cancer treatment using Magnetic particle | October 2021 | May 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17466968 | BAFF-R TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELLS AND USES THEREOF | September 2021 | November 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17462987 | CAR T-CELL THERAPY DIRECTED TO LHR FOR THE TREATMENT OF SOLID TUMORS | August 2021 | June 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17404282 | ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | August 2021 | January 2023 | Abandon | 17 | 2 | 1 | Yes | No |
| 17378110 | HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS | July 2021 | September 2024 | Allow | 38 | 1 | 1 | No | No |
| 17357780 | T CELL RECEPTOR | June 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17353054 | CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE | June 2021 | February 2024 | Allow | 31 | 1 | 0 | No | No |
| 17323993 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | May 2021 | December 2023 | Abandon | 31 | 3 | 0 | No | Yes |
| 17288104 | FUNCTIONALIZED NANOPARTICLE FORMULATIONS FOR ORAL DRUG DELIVERY | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17301884 | T CELL-ANTIGEN COUPLER WITH Y177 MUTATION AND METHODS OF USES THEREOF | April 2021 | October 2021 | Allow | 6 | 1 | 1 | Yes | No |
| 17285774 | LATERAL FLOW ASSAYS FOR DIFFERENTIAL ISOTYPE DETECTION | April 2021 | January 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17230637 | LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR | April 2021 | December 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17276777 | CONDITIONALLY ACTIVE RECEPTORS | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17188011 | CHIMERIC ANTIGEN RECEPTOR THAT BINDS HLA-DR AND CAR-T CELL | March 2021 | December 2023 | Allow | 34 | 1 | 0 | No | No |
| 17141454 | Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same | January 2021 | December 2021 | Allow | 12 | 2 | 1 | Yes | No |
| 15734939 | ANTIBODIES AGAINST AQUACULTURE DISEASE-CAUSING AGENTS AND USES THEREOF | December 2020 | November 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16952678 | PD1 BINDING AGENTS | November 2020 | February 2023 | Allow | 27 | 0 | 0 | No | No |
| 17054193 | Serum Biomarkers | November 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17086762 | PD1 BINDING AGENTS | November 2020 | July 2023 | Allow | 33 | 0 | 1 | No | No |
| 17078969 | CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | October 2020 | April 2024 | Abandon | 42 | 2 | 1 | No | No |
| 16997570 | CD3/CD25 Antibodies For Neuro-Immune Diseases | August 2020 | May 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16921400 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | July 2020 | January 2023 | Allow | 31 | 3 | 1 | Yes | No |
| 16911826 | PD1 BINDING AGENTS | June 2020 | September 2020 | Allow | 3 | 0 | 1 | Yes | No |
| 16912023 | PD1 BINDING AGENTS | June 2020 | September 2020 | Allow | 3 | 0 | 1 | Yes | No |
| 16958105 | CD3-DELTA/EPSILON HETERODIMER SPECIFIC ANTIBODIES | June 2020 | February 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16955608 | Antibodies To Tumour Antigens | June 2020 | December 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16892651 | Method for Combination Cold Atmospheric Plasma and CAR-T Therapy | June 2020 | October 2024 | Abandon | 52 | 3 | 1 | No | No |
| 16891672 | HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS | June 2020 | March 2021 | Allow | 9 | 2 | 1 | No | No |
| 16888427 | DOSING OF BISPECIFIC T CELL ENGAGER | May 2020 | June 2023 | Abandon | 36 | 3 | 0 | No | Yes |
| 15931685 | Methods and Compositions for Preventing Type 1 Diabetes | May 2020 | July 2022 | Allow | 26 | 3 | 0 | Yes | No |
| 16847059 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | April 2020 | March 2023 | Allow | 35 | 0 | 1 | Yes | No |
| 16753577 | T CELL-ANTIGEN COUPLER WITH Y182T MUTATION AND METHODS AND USES THEREOF | April 2020 | January 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16827302 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | March 2020 | March 2021 | Allow | 12 | 1 | 1 | Yes | No |
| 16827381 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | March 2020 | March 2021 | Allow | 12 | 1 | 1 | Yes | No |
| 16807742 | T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF | March 2020 | March 2023 | Allow | 36 | 1 | 1 | No | No |
| 16634325 | CD8 BINDING AGENTS | January 2020 | August 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16632088 | RECOMBINANT CD123-BINDING ANTIBODIES | January 2020 | August 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16741146 | HETERODIMERIC PROTEINS FOR MODULATING GAMMA DELTA T CELLS | January 2020 | June 2021 | Allow | 17 | 2 | 1 | Yes | No |
| 16626233 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF | December 2019 | December 2024 | Allow | 59 | 3 | 1 | No | No |
| 16715462 | CHIMERIC ANTIGEN RECEPTOR THAT BINDS HLA-DR AND CAR-T CELL | December 2019 | April 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16622791 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | December 2019 | March 2024 | Abandon | 51 | 3 | 1 | No | No |
| 16620530 | HUMANIZED DR4 ANTIBODY GENE HAVING APOPTOSIS-INDUCING ACTIVITY AND DUAL-ACTING CHIMERIC ANTIGEN RECEPTOR T CELL OR NATURAL KILLER CELL THERAPEUTIC AGENT USING SAME | December 2019 | January 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16619212 | ANTIGEN-BINDING PROTEIN THAT RECOGNIZES MAGE-A4-DERIVED PEPTIDE | December 2019 | August 2022 | Allow | 33 | 1 | 0 | Yes | No |
| 16615411 | AGENTS WHICH INHIBIT GADS DIMERIZATION AND METHODS OF USE THEREOF | November 2019 | July 2022 | Abandon | 32 | 3 | 1 | No | No |
| 16615360 | CIRCULATING TUMOR CELL ENRICHMENT USING NEOEPITOPES | November 2019 | May 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16677207 | ANTI-PTK7 IMMUNE CELL CANCER THERAPY | November 2019 | July 2024 | Allow | 56 | 4 | 1 | Yes | No |
| 16497682 | Stimulatory Cell Lines For Ex Vivo Expansion And Activation Of Natural Killer Cells | September 2019 | September 2023 | Allow | 48 | 3 | 1 | No | No |
| 16556524 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | August 2019 | June 2022 | Abandon | 33 | 3 | 0 | No | No |
| 16555198 | MODULATION OF CELL FUNCTION FOR IMMUNOTHERAPY | August 2019 | February 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16547910 | ANTI-FC EPSILON-R1 ALPHA (FCER1A) ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND FCER1A AND CD3, AND USES THEREOF | August 2019 | October 2022 | Allow | 38 | 1 | 1 | No | No |
| 16487335 | PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY | August 2019 | March 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16543472 | METHODS FOR IN VIVO EXPANSION OF CD8+ T CELLS AND PREVENTION OR TREATMENT OF GVHD | August 2019 | October 2024 | Abandon | 60 | 5 | 1 | No | No |
| 16485598 | HLA-DR CAR-T COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | August 2019 | September 2023 | Abandon | 49 | 2 | 1 | Yes | No |
| 16481976 | TREATMENT OF CANCER USING CHIMERIC T CELL RECEPTOR PROTEINS HAVING MULTIPLE SPECIFICITIES | July 2019 | September 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16480987 | NYESO TCR | July 2019 | October 2021 | Allow | 27 | 0 | 0 | Yes | No |
| 16512031 | T CELL RECEPTORS THAT BIND TO NY-ESO-1 AND METHODS OF USE THEREOF | July 2019 | November 2022 | Allow | 40 | 1 | 1 | Yes | No |
| 16503984 | NATURAL KILLER CELL EXPRESSING ANTI-COTININE CHIMERIC ANTIGEN RECEPTOR | July 2019 | March 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16472751 | ENGINEERED T CELLS FOR THE TREATMENT OF CANCER | June 2019 | August 2024 | Abandon | 60 | 3 | 1 | Yes | No |
| 16467003 | METHODS AND COMPOSITIONS FOR VACCINATING AND BOOSTING CANCER PATIENTS | June 2019 | January 2022 | Abandon | 31 | 4 | 1 | Yes | No |
| 16465141 | METHODS FOR DETERMINING CAR-T CELLS DOSING | May 2019 | June 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16348378 | HIGH AFFINITY MERKEL CELL POLYOMAVIRUS T ANTIGEN-SPECIFIC TCRS AND USES THEREOF | May 2019 | February 2022 | Allow | 33 | 0 | 1 | Yes | No |
| 16347743 | CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY | May 2019 | September 2023 | Allow | 53 | 3 | 1 | Yes | No |
| 16346226 | ARTIFICIAL ANTIGEN PRESENTING CELLS FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | April 2019 | July 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16343709 | SECRETABLE VARIANT IMMUNOMODULATORY PROTEINS AND ENGINEERED CELL THERAPY | April 2019 | November 2021 | Abandon | 31 | 0 | 1 | No | No |
| 16388245 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF | April 2019 | December 2023 | Abandon | 55 | 3 | 1 | No | No |
| 16339077 | Methods and Kits for Cell Activation | April 2019 | July 2022 | Allow | 40 | 1 | 1 | No | No |
| 16372506 | VHH ANTIBODY | April 2019 | November 2020 | Allow | 19 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HARTNETT, BRIAN.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HARTNETT, BRIAN works in Art Unit 1644 and has examined 145 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner HARTNETT, BRIAN's allowance rate of 60.0% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HARTNETT, BRIAN receive 1.90 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HARTNETT, BRIAN is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +33.8% benefit to allowance rate for applications examined by HARTNETT, BRIAN. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.9% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 45.9% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 37.7% are granted (fully or in part). This grant rate is in the 35% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.